Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04979520 · ClinicalTrials.gov registry record · Early Phase 1
Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
A Early Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT04979520: Completed Early Phase 1 study, sponsored by Rockefeller University.
NCT04979520 is a Early Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 4 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04979520, a Early Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective drug for this disease. Weekly dosing achieved superior therapeutic outcomes compared to a dosing given once in every other week. Brodalumab was safe in both regimens, but blood and tissue studies to better understand this response are still needed. By performing this small pilot study and collecting blood and tissue samples from participants treated with Brodalumab once weekly we would like to better characterize the molecular response to this treatment, identify blood and tissue markers reflecting disease severity, and better understand disease mechanisms.
Primary Outcome
Percentage change in saturation
Interventions
- DRUG Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-08-05 |
| Est. Completion | 2022-07-25 |
| Phase | Early Phase 1 |
What the finished NCT04979520 record still lists
NCT04979520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Brodalumab is the first listed.
NCT04979520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04979520 about?
NCT04979520 is a clinical study titled "Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa". Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective drug for this disease. Weekl...
What is the current status of trial NCT04979520?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2021-08-05. Estimated completion is 2022-07-25.
What interventions are being tested in trial NCT04979520?
The interventions under investigation include: Brodalumab (DRUG).
Who is sponsoring clinical trial NCT04979520?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04979520's enrollment target sits among peer trials
4 1922nd of 2000 higher than 53 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI